Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT04156243 CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Mali… |
CD19 CARvac T cells | SEP | Phase 1 | UNKNOWN | En attente / non publié | iCell Gene Therapeutics | China · Peking University Shenzhen Hospital, Shenzhen… | 2018-02-01 → 2020-02-28 | Ouvrir |
| NCT03720457 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed … |
Human CD19 targeted T Cells Injec… | SEP | Phase 1 | UNKNOWN | En attente / non publié | Hrain Biotechnology Co., Ltd. | China · Fudan University Zhongshan Hospital, Shanghai… | 2018-11-13 → 2023-10 | Ouvrir |
| NCT06279923 CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases |
CD19-BAFF Targeted CAR T-cells | SEP | Phase 1 | RECRUITING | En attente / non publié | Zhejiang University | China · The first affiliated hospital of medical coll… | 2024-04-15 → 2027-02-01 | Ouvrir |
| NCT06828042 Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refrac… |
anti-CD19 CAR T cell therapy | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Peking University Third Hospital | China · Peking University Third Hospital, Beijing, Ch… | 2025-07-01 → 2027-12-31 | Ouvrir |
| NCT07582159 Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chro… |
Acalabrutinib | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | City of Hope Medical Center | United States · City of Hope at Irvine Lennar, Irvine… | 2026-12-19 → 2029-04-14 | Ouvrir |
| NCT03824951 Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymp… |
Anti-CD19 iCAR NK Cells | SEP | Phase 1 | UNKNOWN | En attente / non publié | Allife Medical Science and Techno… | Non communiqué | 2019-02-01 → 2021-01-01 | Ouvrir |
| NCT04486872 An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of D… |
Autologous humanized anti-CD19 an… | SEP | Phase 1 | UNKNOWN | En attente / non publié | First Affiliated Hospital of Zhej… | China · First Affiliated Hospital of Zhejiang Univers… | 2020-07-25 → 2022-06-25 | Ouvrir |
| NCT06591429 Smoldering Inflammation in MS |
Radiotracer [11C]-CS1P1 | SEP | À vérifier | RECRUITING | En attente / non publié | Washington University School of M… | United States · Barnes Jewish Center for Clinical Ima… | 2024-06-19 → 2027-06-30 | Ouvrir |
| NCT02538926 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxor… |
Asparaginase | SEP | Phase 2 | WITHDRAWN | En attente / non publié | University of Washington | United States · Fred Hutchinson Cancer Research Cente… | 2018-07-01 → 2021-07-30 | Ouvrir |
| NCT00003595 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in… |
Filgrastim | SEP | Phase 3 | COMPLETED | En attente / non publié | National Cancer Institute (NCI) | United States · Arthur G. James Cancer Hospital - Ohi… | 1999-01 | Ouvrir |
| NCT07110194 Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positi… |
TQB2825 Injection (Subcutaneous I… | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Shanghai Chia Tai Tianqing Pharma… | China · Beijing Cancer Hospital, Beijing, China | 2025-09 → 2027-12 | Ouvrir |
| NCT04361279 A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previo… |
SIBP-02 | SEP | Phase 3 | COMPLETED | En attente / non publié | Shanghai Institute Of Biological … | China · The First Affiliated Hospital of College of M… | 2019-07-25 → 2022-05-20 | Ouvrir |
| NCT00818961 Donor Stem Cell Transplant in Treating Patients With High-Risk Hematolo… |
Alemtuzumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Northside Hospital, Inc. | United States · Blood and Marrow Transplant Group of … | 2005-05 → 2012-03 | Ouvrir |
| NCT03379051 Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ubli… |
Venetoclax | SEP | Phase 1/2 | TERMINATED | En attente / non publié | TG Therapeutics, Inc. | United States · TG Therapeutics Investigational Trial… | 2018-03-27 → 2022-06-16 | Ouvrir |
| NCT07854483 A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (S… |
C-CAR168 | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | RenJi Hospital | Non communiqué | 2027-03 → 2030-03 | Ouvrir |
| NCT01066728 CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity |
Theophylline | SEP | Phase 2/3 | COMPLETED | En attente / non publié | Massachusetts General Hospital | Canada · Health Sciences Centre, Winnipeg, Canada | S… | 2001-08 → 2007-03 | Ouvrir |
| NCT00252863 DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Ther… |
Symbicort, used twice daily (b.i.… | SEP | Phase 3 | COMPLETED | En attente / non publié | AstraZeneca | Germany · Research Site, Amberg, Germany | Research S… | 2004-12 → 2006-05 | Ouvrir |
| NCT01902758 Drug Combination on Exercise Performance at High Altitude |
ambrisentan and theophylline | SEP | Phase 2/3 | COMPLETED | En attente / non publié | University of Montana | United States · Montana Center for Work Physiology an… | 2013-08 → 2013-08 | Ouvrir |
| NCT03115294 CardiomeDIC — Digital Image Correlation in Right Ventricular Evaluation |
Theophylline | SEP | Non applicable | COMPLETED | En attente / non publié | Massachusetts General Hospital | Finland · Tampere University Hospital, Heart Center, … | 2016-05-16 → 2019-10-21 | Ouvrir |
| NCT06782490 MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-… |
BMS-986368 | Myopathies | Phase 2 | RECRUITING | En attente / non publié | Celgene | United States, Australia, Canada, Czechia, Germany, P… | 2025-06-05 → 2027-06-09 | Ouvrir |
| NCT02888132 Echocardiography-guided Transthoracic Radio Frequency/Laser Ablation fo… |
Echocardiography-guided transthor… | Cancer | Non applicable | UNKNOWN | En attente / non publié | Xijing Hospital | China · Ultrasound Medicine Department of Xijing Hosp… | 2016-04 | Ouvrir |
| NCT07672483 IL-12 Genetically Engineered Myeloid Cells in Participants With Relapse… |
IL-12 GEMys | Cancer | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2026-10-07 → 2029-01-15 | Ouvrir |
| NCT06769659 A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years… |
NPT 2042 | Épilepsie | Phase 2 | COMPLETED | En attente / non publié | NeuroPro Therapeutics, Inc. | United States · Clinical Trials, Inc. (CTI), Little R… | 2025-03-11 → 2026-09-23 | Ouvrir |
| NCT02531880 Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic… |
Mangafodipir | Épilepsie | Phase 1 | RECRUITING | En attente / non publié | National Institute of Neurologica… | United States · National Institutes of Health Clinica… | 2024-11-19 → 2030-07-01 | Ouvrir |
| NCT04855617 Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclero… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Elliot Lewis Center for Multiple Scle… | 2020-10-26 → 2022-10-01 | Ouvrir |